Emergent Biosolutions Inc.

Emergent BioSolutions Inc. exercised a $20M contract option with the U.S. DoD to supply BioThrax®, an anthrax vaccine, starting deliveries in December 2024. This supports U.S. military's pre-exposure prophylaxis against anthrax, highlighting Emergent's commitment to public health threats.

Innovative ROR1-targeting therapies, including zilovertamab vedotin and CS5001, show promise in cancer treatment. Zilovertamab vedotin achieved a 100% complete response rate in a Phase 2 trial for DLBCL. CS5001 demonstrated clinical activity in both solid tumors and lymphomas, with an overall ORR of 48.4%. These advancements highlight the potential of ROR1-targeted therapies in offering precise and effective cancer treatments.

Emergent BioSolutions announces brincidofovir (TEMBEXA®) inclusion in PANTHER-led clinical trial under Africa CDC for mpox treatment.

Emergent BioSolutions announces brincidofovir (TEMBEXA®) inclusion in PANTHER-led clinical trial under Africa CDC for mpox treatment, aiming to evaluate safety and efficacy in a randomized double-blind placebo-controlled study.

Emergent BioSolutions appoints Dr. Simon Lowry as chief medical officer, head of research and development, effective November 18, to advance the company's strategic scientific roadmap. Jessica Perl is promoted to General Counsel and Corporate Secretary.

Greenlane Holdings, Inc. (NASDAQ: GNLN) plans to launch fentanyl, xylazine, and drink spike detection test strips under the Safety Strips brand, available from September 25th. The global opioid overdose treatment market is expected to reach $1.54 billion in 2024, with a projected CAGR of 7.2% through 2034.

S&P Global Ratings provides financial intelligence and analytical tools for global capital markets.

Bavarian Nordic A/S faces pressure to lower its mpox vaccine price for Africa, currently at $100-$141 per dose, as talks with agencies like Unicef aim to secure 12 million doses by 2025. Critics argue the high cost is prohibitive for African nations dealing with multiple health crises, urging discounts or generic production. Bavarian Nordic acknowledges pricing challenges but seeks a balance to ensure vaccine availability.

Emergent BioSolutions' ACAM2000 vaccine approved by FDA for mpox prevention in high-risk individuals, based on safety data and animal study efficacy.